Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable

被引：7

作者：

Buttar, David ^{[1
]}

Edge, Mike ^{[1
]}

Emery, Steve C. ^{[1
]}

Fitzek, Martina ^{[1
]}

Forder, Cheryl ^{[1
]}

Griffen, Alison ^{[1
]}

Hayter, Barry ^{[1
]}

Hayward, Chris F. ^{[1
]}

Hopcroft, Philip J. ^{[1
]}

Luke, Richard W. A. ^{[1
]}

Page, Ken ^{[1
]}

Stawpert, John ^{[1
]}

Wright, Andy ^{[1
]}

机构：

[1] AstraZeneca, Canc & Infect Res Area, Mereside, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 16期

关键词：

angiogenesis; kinase; Tie-2; inhibitor; pyrimidine; imidazole; alkene;

D O I：

10.1016/j.bmcl.2008.06.106

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tie-2 is a receptor tyrosine kinase which is involved in angiogenesis and thereby growth of human tumours. The discovery and SAR of a novel class of imidazole-vinyl-pyrimidine kinase inhibitors, which inhibit Tie-2 in vitro is reported. Their synthesis was carried out by condensation of imidazole aldehydes with methyl pyrimidines. These compounds are lead-like, with low molecular weight, good physical properties and oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4723 / 4726

页数：4

共 50 条

[21] Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
Degorce, Sebastien L.
Barlaam, Bernard
Cadogan, Elaine
Dishington, Allan
Ducray, Richard
Glossop, Steven C.
Hassall, Lorraine A.
Lach, Franck
Lau, Alan
McGuire, Thomas M.
Nowak, Thorsten
Ouvry, Gilles
Pike, Kurt G.
Thomason, Andrew G.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (13) : 6281 - 6292
[22] Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
Takeuchi, Craig S.
Kim, Byung Gyu
Blazey, Charles M.
Ma, Sunghoon
Johnson, Henry W. B.
Anand, Neel K.
Arcalas, Arlyn
Baik, Tae Gon
Buhr, Chris A.
Cannoy, Jonah
Epshteyn, Sergey
Joshi, Anagha
Lara, Katherine
Lee, Matthew S.
Wang, Longcheng
Leahy, James W.
Nuss, John M.
Aay, Naing
Aoyama, Ron
Foster, Paul
Lee, Jae
Lehoux, Isabelle
Munagala, Narsimha
Plonowski, Arthur
Rajan, Sharmila
Woolfrey, John
Yamaguchi, Kyoko
Lamb, Peter
Miller, Nicole
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2218 - 2234
[23] Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2
Liu, Qiufeng
Huang, Fubao
Yuan, Xiaojing
Wang, Kai
Zou, Yi
Shen, Jianhua
Xu, Yechun
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (24) : 10231 - 10244
[24] Discovery and optimization of quinazolinone-pyrrolo-dihydropyrrolones as potent, selective, and orally bioavailable Pim1,2,3 kinase inhibitors
Pettus, Liping
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[25] Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors
Calvo, Veronica
Surguladze, David
Li, An-Hu
Surman, Matthew D.
Malibhatla, Srikanth
Bandaru, Madhavarao
Jonnalagadda, Suresh Krishna
Adarasandi, Ravi
Velmala, Madhusudhan
Singireddi, Durga Rama Prasad
Velpuri, Mahendar
Nareddy, Bhaskar Reddy
Sastry, Visweswara
Mandati, Chiranjeevi
Guguloth, Rambabu
Siddiqui, Shapi
Patil, Basanagoud S.
Chad, Elena
Wolfley, Jennifer
Gasparek, Jennifer
Feldman, Kirsten
Betzenhauser, Matthew
Wiens, Brent
Koszelak-Rosenblum, Mary
Zhu, Guangyu
Du, Hongwen
Rigby, Alan C.
Mulvihill, Mark J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 43
[26] Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun NH2-terminal kinase inhibitors
Zhao, Hongyu
Serby, Michael D.
Xin, Zhili
Szczepankiewicz, Bruce G.
Liu, Mei
Kosogof, Christi
Liu, Bo
Nelson, Lissa T. J.
Johnson, Eric F.
Wang, Sanyi
Pederson, Terry
Gum, Rebecca J.
Clampit, Jill E.
Haasch, Deanna L.
Abad-Zapatero, Cele
Fry, Elizabeth H.
Rondinone, Cristina
Trevillyan, James M.
Sham, Hing L.
Liu, Gang
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) : 4455 - 4458
[27] Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments
Latif, Muhammad
Ashraf, Zaman
Basit, Sulman
Ghaffar, Abdul
Zafar, Muhammad Sohail
Saeed, Aamer
Meo, Sultan Ayoub
[J]. RSC ADVANCES, 2018, 8 (30) : 16470 - 16493
[28] Discovery of Novel 2-N-Aryl-Substituted Benzenesulfonamidoacetamides: Orally Bioavailable Tubulin Polymerization Inhibitors with Marked Antitumor Activities
Liu, Zulong
Zhou, Zuyu
Tian, Wei
Fan, Xing
Xue, Ding
Yu, Long
Yu, Qiang
Long, Ya-Qiu
[J]. CHEMMEDCHEM, 2012, 7 (04) : 680 - 693
[29] Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2
Clark, Michael P.
Ledeboer, Mark W.
Davies, Ioana
Byrn, Randal A.
Jones, Steven M.
Perola, Emanuele
Tsai, Alice
Jacobs, Marc
Nti-Addae, Kwame
Bandarage, Upul K.
Boyd, Michael J.
Bethiel, Randy S.
Court, John J.
Deng, Hongbo
Duffy, John P.
Dorsch, Warren A.
Farmer, Luc J.
Gao, Huai
Gu, Wenxin
Jackson, Katrina
Jacobs, Dylan H.
Kennedy, Joseph M.
Ledford, Brian
Liang, Jianglin
Maltais, Francois
Murcko, Mark
Wang, Tiansheng
Wannamaker, M. Woods
Bennett, Hamilton B.
Leeman, Joshua R.
McNeil, Colleen
Taylor, William P.
Memmott, Christine
Jiang, Min
Rijnbrand, Rene
Bral, Christopher
Germann, Ursula
Nezami, Azin
Zhang, Yuegang
Salituro, Francesco G.
Bennani, Youssef L.
Charifson, Paul S.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (15) : 6668 - 6678
[30] Discovery of VX-787: A novel, first-in-class, orally bioavailable azaindole inhibitor of influenza PB2
Clark, Michael P.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248

← 1 2 3 4 5 →